Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Basic Materials, Industrials and Healthcare sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Oil & Gas, Industrials and Financials sectors led shares lower. At the close in NYSE, the Dow...
Investing.com - Just a little patience was enough to send stocks soaring Friday. Wall Street, already buoyed by an exceptionally strong nonfarm payrolls report, shot up in morning...
Flex Pharma Inc. (NASDAQ:FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company discontinued the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Sell | Sell |
| Summary | Strong Sell | Strong Sell | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 331.26 | 332.83 | 328.93 | -1.20 | -0.36% | 13.59M | NASDAQ | |||
| 2,430.20 | 2,441.72 | 2,418.96 | -4.93 | -0.20% | 1.10M | NASDAQ | |||
| 14.11 | 14.25 | 13.82 | -0.09 | -0.63% | 1.51M | NYSE | |||
| 271.45 | 271.90 | 268.40 | +1.98 | +0.73% | 4.49M | NASDAQ | |||
| 30.08 | 30.20 | 29.85 | +0.11 | +0.37% | 11.42M | NYSE | |||
| 45.68 | 46.26 | 42.76 | +2.92 | +6.83% | 85.73M | NYSE | |||
| 11.13 | 11.35 | 11.06 | +0.02 | +0.18% | 381.38K | NASDAQ | |||
| 2,513.93 | 2,526.99 | 2,498.29 | -7.67 | -0.30% | 1.26M | NASDAQ | |||
| 300.45 | 302.17 | 299.26 | +1.85 | +0.62% | 710.38K | NYSE | |||
| 4.79 | 5.18 | 4.69 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 211.64 | 213.46 | 211.00 | -1.43 | -0.67% | 12.28M | NYSE | |||
| 60.50 | 60.63 | 59.87 | +0.20 | +0.33% | 6.98M | NYSE | |||
| 134.62 | 134.65 | 133.65 | +0.40 | +0.30% | 6.53M | NASDAQ | |||
| 226.38 | 226.78 | 219.00 | +4.26 | +1.92% | 1.68M | NASDAQ | |||
| 107.91 | 108.97 | 107.86 | -0.50 | -0.46% | 7.73M | NYSE |
Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
